HSV1 - The Market
The total skin disorders market is estimated to be $28 Billion annually (for 2011), about 1/3 of which is due to viral infections, most of these being the Herpes virus (HSV1, HSV2 and Herpes Zoster)
By the age of 40, nearly 90% of adults, have been exposed to HSV1, 15% of those exposed to HSV1 may develop symptoms (blisters, cold sores) every year.
In the Western World (U.S., Europe and Japan) the potential market is over 100 Million patients, these patients develop clinical symptoms every year.
Globally, about 4.0 billion people are estimated to be infected with Herpes Virus
The incidence rate of cold sores, caused by the HSV1 virus, is the second largest worldwide, trailing only behind common cold
About 79% of the U.S. population is infected with HSV1, with about 25-35% of the adults enduring recurrent spate of cold Sores
in recent years HSV1 has become the most common cause of newly diagnosed genital herpes infections
”The need for innovative therapies for the treatment of herpes simplex infection, and the search for novel antiviral drugs continues. This presents a huge potential for the growth of herpes simplex therapeutics market in future”.
Above 40% of genital Herpes is caused by HSV1 and Zep-3 presents a possible prevention as well as cure. Psoriasis is a chronic skin disease that is the most prevalent autoimmune disease in the U.S., with as many as 7.5 million Americans affected (2.45% of the population).
Psoriasis Market Info™ captures all the relevant data on this disease. The overall market value is $1.8+ billion in 2010 in the U.S alone and $3.4 billion world-wide. This market is expected to grow significantly in the future, largely due to the chronic nature of the disease, the high unmet and continued need for topical therapies which will make this market approachable for any new therapy that is both effective and safe.